Eikon Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
62.5%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$6.35next fiscal year
Monitoring Framework
Key Performance Indicators
EIK1001 Objective Response Rate (ORR) in first-line NSCLC Annually63.1%Target: Demonstrate competitive efficacy compared to standard of care alone
EIK1001 Disease Control Rate (DCR) in first-line NSCLC Annually90.8%Target: Maintain high disease control in combination with pembrolizumab and chemotherapy
EIK1003 Objective Response Rate (ORR) in PARP-naïve patients Annually26.7%Target: Establish monotherapy efficacy in advanced solid tumors
Cash Runway (Years) Quarterly1.5Target: Fund operations through key clinical readouts into late 2027
Watch Items
- EIK1001 Phase 2/3 registrational trial interim analysis in advanced melanomaTrigger: First interim analysis expected in the second half of 2026Action: Select optimal dose and determine path to registration based on efficacy and safety
- EIK1001 Phase 2/3 registrational trial initiation in stage 4 NSCLCTrigger: Dosing of the first patient expected in the second half of 2026Action: Monitor trial site activation and patient enrollment rates
- EIK1003 Phase 1/2 trial cohort expansionTrigger: Initiation of Cohort 1D combining EIK1003 with platinum and paclitaxel in 2H 2026Action: Evaluate safety, tolerability, and hematological toxicity profiles
- Insider lock-up period expirationTrigger: Expiration in August 2026Action: Assess potential market selling pressure and impact on stock price stability
Research as of 24 Jul 2026